Georgina Long

The University of Sydney - Melanoma Institute Australia

Sydney

Australia

SCHOLARLY PAPERS

2

DOWNLOADS

49

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

Epacadostat Plus Pembrolizumab versus Placebo Plus Pembrolizumab in Patients with Unresectable or Metastatic Melanoma: Results of the Phase 3, Randomised, Double-Blind Echo-301/Keynote-252 Study

Number of pages: 39 Posted: 05 Feb 2019
The University of Sydney - Melanoma Institute Australia, University Hospital Zurich, Angeles Clinic and Research Institute, University of Chicago - Medical Center, Universidad del Desarrollo - Facultad de Medicina Clínica Alemana, University of Lyon 1, Hospital Clinic of Barcelona, The University of Sydney - Melanoma Institute Australia, Aix-Marseille University, Seoul National University - Seoul National Hospital, N.N. Blokhin Russian Cancer Research Center, Université Paris XI Sud - Gustave Roussy Cancer Campus, Royal Marsden NHS Foundation Trust, Merck & Co., Inc., Incyte Corporation, Incyte Corporation, Merck & Co., Inc. and University of Pennsylvania, Perelman School of Medicine, Abramson Family Cancer Research Institute
Downloads 35 (455,326)

Abstract:

Loading...

melanoma, indoleamine 2,3-dioxygenase, epacadostat, pembrolizumab, immunotherapy

2.

Tumor CD155 Drives Resistance to Immunotherapy by Downregulating the Activating Receptor CD226 in CD8 + T Cells

IMMUNITY-D-19-01000
Number of pages: 75 Posted: 10 Oct 2019
QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Oncology and Cellular Immunology Laboratory, QIMR Berghofer Medical Research Institute - Oncology and Cellular Immunology Laboratory, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Oncology and Cellular Immunology Laboratory, QIMR Berghofer Medical Research Institute - Gordon and Jessie Gilmour Leukemia Laboratory, University of Bonn - Institute of Experimental Oncology, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, Bristol-Myers Squibb - Immuno-Oncology Discovery, Institut de recherches cliniques de Montréal (IRCM) - Laboratory of Molecular Oncology, University of Bonn - Institute of Experimental Oncology, University of Queensland - Pathology Queensland, The University of Sydney - Melanoma Institute Australia, The University of Sydney - Melanoma Institute Australia, The University of Sydney - Melanoma Institute Australia, University of Queensland - Royal Brisbane and Women’s Hospital, QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory, Bristol-Myers Squibb - Immuno-Oncology Discovery, University of Toulouse 3, Paul Sabatier University - Cancer Research Center of Toulouse (CRCT), QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory and QIMR Berghofer Medical Research Institute - Immunology in Cancer and Infection Laboratory
Downloads 14 (570,531)

Abstract:

Loading...

Dysfunctional CD8+ T cells, CD226 (DNAM-1), CD155 (PVR), Cancer immunotherapy, Melanoma, HNSCC, adoptive cell transfer therapy